KAYLA SMITH: Open Payments
NPI 1215422480 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,298 in 50 payments from 9 companies in 2025. Trend: 2023 $1,139 · 2024 $1,225 · 2025 $1,298
Food & beverage: $1,298
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $235 |
| Alnylam Pharmaceuticals Inc. | 9 | $223 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $206 |
| Merck Sharp & Dohme LLC | 6 | $169 |
| PFIZER INC. | 10 | $159 |
| UCB, Inc. | 1 | $129 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $110 |
| BridgeBio Pharma, Inc. | 2 | $36 |
| SCPHARMACEUTICALS INC. | 2 | $32 |
Products named: AMVUTTRA, Kerendia, Rystiggo, FARXIGA, VERQUVO, WAINUA, JARDIANCE, VYNDAQEL.
Industry payments across MS — which companies pay providers there.
